Patient NAME : Mr.

Krishnendu Basak Barcode NO : 12362429

Age/Gender : 24 Y/ Male Registration ON : 12- Jan- 2024 02: 47: 14 PM
LabNo : 012401120688 Sample Collected ON : 12/ Jan/ 2024 02: 47: 14 PM
Referred BY : Dr. SELF Sample Received ON : 12/ Jan/ 2024 03: 01: 29 PM
CLIENT CODE : WBCL/ CORP/ PTPL Report Generated ON : 12/ Jan/ 2024 04: 05: 25 PM
Refer Lab/Hosp : Sample STATUS : Final Approved
Lab Address : AS 130, Block-H, Rajarhat Main Road, Kolkata 700157

DEPARTMENT OF HEMATOLOGY
Medibuddy 1 9 7 .0 -MediBuddy - TCS Wellness Package Onsite

Test Name Value Unit Bio Ref.Interval

ESR 8 mm in 1hr 10 or less

(Method:Westergren method) (Sample:EDTA Whole Blood)

PBS - Peripheral Blood Smear Examination

Morphology
RBC Morphology Normocytic and Normochromic.
(Method:Microscopic) (Sample:EDTA )
WBC Morphology Lymphocytosis
(Method:Microscopic) (Sample:EDTA )
Platelet Morophology Adequate.

CBC - Extended
Erythrocytes
Haemoglobin 13.5 g/ dL 13-17
(Method:Spectrophotometry) (Sample:EDTA)
RBC Count 4.6 10^ 12/ L 4.5-5.5
(Method:Cell Impedance) (Sample:EDTA)
PCV (Packed Cell Volume) 40.1 % 40-50
(Method:Calculated ) (Sample:EDTA)
MCV (Mean Corpuscular Volume) 87.2 fl 81-101
(Method:Calculated) (Sample:EDTA)
MCH (Mean Corpuscular Hemoglobin) 29.35 pg 27-32
(Method:Calculated) (Sample:EDTA)
MCHC (Mean Corpuscular Hemoglobin 33.7 g/ dL 32.5-34.5
Concentration)
(Method:Calculated) (Sample:EDTA)
PDW 13.50 % 9 - 17
(Method:Calculated ) (Sample:EDTA)
MPV 14.20 fL 7.0-11.0
(Method:Cell Impedence -Cell Counter) (Sample:EDTA)
RDW-CV 13.0 % 11.6-14.0
(Method:Calculated) (Sample:EDTA)
RDW-SD 38.0 fL 40 - 55
(Method:Calculated ) (Sample:EDTA)
Leucocytes

Page 1 of 10
Patient NAME : Mr.Krishnendu Basak Barcode NO : 12362429
Age/Gender : 24 Y/ Male Registration ON : 12- Jan- 2024 02: 47: 14 PM
LabNo : 012401120688 Sample Collected ON : 12/ Jan/ 2024 02: 47: 14 PM
Referred BY : Dr. SELF Sample Received ON : 12/ Jan/ 2024 03: 01: 29 PM
CLIENT CODE : WBCL/ CORP/ PTPL Report Generated ON : 12/ Jan/ 2024 04: 05: 25 PM
Refer Lab/Hosp : Sample STATUS : Final Approved
Lab Address : AS 130, Block-H, Rajarhat Main Road, Kolkata 700157

DEPARTMENT OF HEMATOLOGY
Medibuddy 1 9 7 .0 -MediBuddy - TCS Wellness Package Onsite

Test Name Value Unit Bio Ref.Interval

WBC Count,Total 5,200 Cells/µL 4,000-11,000
(Method:Cell Impedance) (Sample:EDTA)
Differential Leucocyte Count
Neutrophils 42 % 40-70
(Method:Cell Impedance) (Sample:EDTA)
Lymphocytes 53 % 20-40
(Method:Cell Impedance) (Sample:EDTA)
Monocytes 2 % 2-10
(Method:Cell Impedance) (Sample:EDTA)
Eosinophils 3 % 1-6
(Method:Cell Impedance) (Sample:EDTA)
Basophils 0 % 0-2
(Method:Cell Impedance) (Sample:EDTA)
Absolute Neutrophil Count 2,184 Cells/µL 2000-7000
(Method:Calculated) (Sample:EDTA)
Absolute Lymphocyte Count 2,756 Cells/µL 1000-3000
(Method:Calculated) (Sample:EDTA)
Absolute Monocyte Count 104 Cells/µL 20 - 500
(Method:Calculated) (Sample:EDTA)
Absolute Eosinophil Count 156 cells/µL 20-500
(Method:Calculated) (Sample:EDTA)
Absolute Basophil Count 0 Cells/µL <200
(Method:Calculated) (Sample:EDTA)
Thrombocytes
Platelet Count 346 10^ 9/ L 150-410
(Method:Cell Impedance ) (Sample:EDTA)
P-LCR 0.356 % 15 - 35
(Method:Calculated ) (Sample:EDTA)
PCT 0.241 mL/ L
(Method:Calculated ) (Sample:EDTA)
Mixed Cells 0.6 -
Erythrocyte Sedimentation Rate
ESR 8 mm in 1hr 10 or less
(Method:Westergren method) (Sample:EDTA)

Page 2 of 10
Patient NAME : Mr.Krishnendu Basak Barcode NO : 12362429
Age/Gender : 24 Y/ Male Registration ON : 12- Jan- 2024 02: 47: 14 PM
LabNo : 012401120688 Sample Collected ON : 12/ Jan/ 2024 02: 47: 14 PM
Referred BY : Dr. SELF Sample Received ON : 12/ Jan/ 2024 03: 01: 29 PM
CLIENT CODE : WBCL/ CORP/ PTPL Report Generated ON : 12/ Jan/ 2024 04: 45: 17 PM
Refer Lab/Hosp : Sample STATUS : Final Approved
Lab Address : AS 130, Block-H, Rajarhat Main Road, Kolkata 700157

DEPARTMENT OF BIOCHEMISTRY
Medibuddy 1 9 7 .0 -MediBuddy - TCS Wellness Package Onsite

Test Name Value Unit Bio Ref.Interval

Glucose - Fasting 102 mg/ dL Adults:74-106

(Method:Hexokinase) (Sample:Fluoride Plasma) Children:60-100
Pre-Diabetic: 111 - 125
Diabetic: ≥ 126
Please clinically correlate. Partial reproduction of test reports is strictly prohibited.
The reports are strictly for the use of medical practitioners and are not medical diagnosis.
Com m ent s:
Glucose is a reducing monosaccharide that serves as the principal fuel for all tissues. It enters the cell through the influence of insulin and undergoes a series of chemical reactions to produce
energy. Lack of insulin or resistance to its action at the cellular level causes diabetes. Therefore, in diabetes mellitus, the blood glucose levels are very high. Hyperglycemia is also noted in
gestational diabetes during pregnancy and may be found in pancreatic disease, pituitary, and adrenal disorders. A decreased level of blood glucose and hypoglycemia is often associated with
starvation, hyperinsulinemia, and in those who are taking high insulin doses for therapy. Clinical diagnosis should not be made on the findings of a single test result but should integrate both
clinical and laboratory data.
Note: For pre-hyperglycemic results please repeat the test with fresh samples for 2 consecutive days recommended.
Reference: www.who.int/ diabetes/ publications/

Sodium (Na) 142 mmol/ L 135 - 145

(Method:ISE Direct) (Sample:Serum)
Please clinically correlate. Partial reproduction of test reports is strictly prohibited.
The reports are strictly for the use of medical practitioners and are not medical diagnosis.
Comments:

Sodium and other electrolytes such as potassium, chloride, and bicarbonate (or total CO2 ) help cells function normally and helps regulate the amount of fluid in the
body. While sodium is present in all body fluids, it is found in the highest concentration in the blood and in the fluid outside of the body's cells. This extracellular
sodium, as well as all body water, is regulated by the kidneys.

Potassium (K) 4.4 mmol/ L 3.5 - 5.0

(Method:ISE Direct) (Sample:Serum)
Please clinically correlate. Partial reproduction of test reports is strictly prohibited.
The reports are strictly for the use of medical practitioners and are not medical diagnosis.
Com m ent s:

Potassium is an electrolyte that is vital to cell metabolism. It helps transport nutrients into cells and removes waste products out of cells. It is also important in muscle
function, helping to transmit messages between nerves and muscles.
Because the blood concentration of potassium is so small, minor changes can have significant health effects. Potassium levels that are too low or too high can alter the
function of the nerves and muscles and there can be serious health complications, such as shock, breathing problems (respiratory failure), irregular heart beat, or the
heart muscle may even lose its ability to contract.
Measuring potassium as part of an electrolyte or metabolic panel may help diagnose an electrolyte imbalance or acidosis or alkalosis. Acidosis and alkalosis describe

Page 3 of 10
Patient NAME : Mr.Krishnendu Basak Barcode NO : 12362429
Age/Gender : 24 Y/ Male Registration ON : 12- Jan- 2024 02: 47: 14 PM
LabNo : 012401120688 Sample Collected ON : 12/ Jan/ 2024 02: 47: 14 PM
Referred BY : Dr. SELF Sample Received ON : 12/ Jan/ 2024 03: 01: 29 PM
CLIENT CODE : WBCL/ CORP/ PTPL Report Generated ON : 12/ Jan/ 2024 04: 45: 17 PM
Refer Lab/Hosp : Sample STATUS : Final Approved
Lab Address : AS 130, Block-H, Rajarhat Main Road, Kolkata 700157

DEPARTMENT OF BIOCHEMISTRY
Medibuddy 1 9 7 .0 -MediBuddy - TCS Wellness Package Onsite

Test Name Value Unit Bio Ref.Interval

the abnormal conditions that result from an imbalance in the pH of the blood caused by an excess of acid or alkali (base). This imbalance is typically caused by some
underlying condition or disease.

Chloride 101 mmol/ L 98-107

(Method:ISE – Indirect) (Sample:Serum)
Please clinically correlate. Partial reproduction of test reports is strictly prohibited.
The reports are strictly for the use of medical practitioners and are not medical diagnosis.
High levels of chloride may indicate:

Dehydration

Kidney disease

Acidosis, a condition in which you have too much acid in your blood. It can cause nausea, vomiting, and fatigue.

Alkalosis, a condition in which you have too much base in your blood. It can cause irritability, muscle twitching, and tingling in the fingers and toes.

Low levels of chloride may indicate:

Heart failure

Lung diseases

Addison's disease, a condition in which your body's adrenal glands don't produce enough of certain types of hormones. It can cause a variety of symptoms,
including weakness, dizziness, weight loss, and dehydration.

Lipid Profile With Ratio - 1.0

Cholesterol Total 174 mg/ dL Desirable< 200
(Method:CHOD POD ) (Sample:Serum) Borderline High-200-239
High- 240
Cholesterol - HDL 48 mg/ dL Major risk factor for heart
(Method:Direct Homogenous) (Sample:Serum) disease < 40

Page 4 of 10
Patient NAME : Mr.Krishnendu Basak Barcode NO : 12362429
Age/Gender : 24 Y/ Male Registration ON : 12- Jan- 2024 02: 47: 14 PM
LabNo : 012401120688 Sample Collected ON : 12/ Jan/ 2024 02: 47: 14 PM
Referred BY : Dr. SELF Sample Received ON : 12/ Jan/ 2024 03: 01: 29 PM
CLIENT CODE : WBCL/ CORP/ PTPL Report Generated ON : 12/ Jan/ 2024 04: 45: 17 PM
Refer Lab/Hosp : Sample STATUS : Final Approved
Lab Address : AS 130, Block-H, Rajarhat Main Road, Kolkata 700157

DEPARTMENT OF BIOCHEMISTRY
Medibuddy 1 9 7 .0 -MediBuddy - TCS Wellness Package Onsite

Test Name Value Unit Bio Ref.Interval

Negative risk factor for heart
disease >60
Cholesterol - Non-HDL 126 mg/ dL Optimal < 130
(Method:Calculated) (Sample:Serum)
Cholesterol VLDL 21 mg/ dL 7 - 40
(Method:Calculated) (Sample:Serum)
Cholesterol - LDL 105 mg/ dL <100 Optimal
(Method:Calculated) (Sample:Serum)
Triglycerides 104 mg/ dL Normal: < 150
(Method:GPO-POD) (Sample:Serum) Borderline: 150-199
High: >200
LDL / HDL Ratio 2.2 0-3.5
HDL / LDL Ratio 0.5 -
Total Cholesterol/ HDL Ratio 3.6 -

Liver Function Test (LFT) - With Ratio 1.1

Bilirubin Total 0.64 mg/ dL Adults- 0.3-1.2
(Method:DPD) (Sample:Serum) Children (0-1 Day) 1.4-8.7
Children (1-2 Day) 3.4-11.5
Children (3-5 Day) 1.5-12.0
Bilirubin Direct 0.15 mg/ dL 0.1 - 0.2
(Method:DPD) (Sample:Serum)
Bilirubin Indirect 0.49 mg/ dl 0.2-0.8
(Method:Calculated) (Sample:Serum)
Alkaline Phosphotase (ALP) 73 U/ L 53-128
(Method:IFCC ) (Sample:Serum)
AST/ SGOT 63 U/ L Male ≤ 50
(Method:IFCC ) (Sample:Serum) Female ≤ 35
New Born : 25-75
Infant:15-60
ALT/ SGPT 110 U/ L Male ≤ 50
(Method:IFCC ) (Sample:Serum) Female ≤ 35
New Born:13-45
Infant:13-45
SGOT/ SGPT Ratio 0.57
Protein Total 7.6 g/ dL Newborn: 4.1-6.3

Page 5 of 10
Patient NAME : Mr.Krishnendu Basak Barcode NO : 12362429
Age/Gender : 24 Y/ Male Registration ON : 12- Jan- 2024 02: 47: 14 PM
LabNo : 012401120688 Sample Collected ON : 12/ Jan/ 2024 02: 47: 14 PM
Referred BY : Dr. SELF Sample Received ON : 12/ Jan/ 2024 03: 01: 29 PM
CLIENT CODE : WBCL/ CORP/ PTPL Report Generated ON : 12/ Jan/ 2024 04: 45: 17 PM
Refer Lab/Hosp : Sample STATUS : Final Approved
Lab Address : AS 130, Block-H, Rajarhat Main Road, Kolkata 700157

DEPARTMENT OF BIOCHEMISTRY
Medibuddy 1 9 7 .0 -MediBuddy - TCS Wellness Package Onsite

Test Name Value Unit Bio Ref.Interval

(Method:Biuret) (Sample:Serum) Children:5.7-8.0
Adults: 6.6-8.3
Albumin 4.4 g/ dL Adults- 3.5-5.2
(Method:BCG) (Sample:Serum) New Born- 2.8 – 4.4
Globulin 3.2 g/ dL 2.3 - 3.9
(Method:Calculated) (Sample:Serum)
Albumin / Globulin Ratio 1.4 -
(Method:Calculated) (Sample:Serum)
Gamma Glutamyl Transferase (GGT) 39.0 U/ L Male : <55
(Method:IFCC) (Sample:Serum) Female: <38

Kidney/ Renal Panel - 1.1

Urea 19.0 mg/ dL 17 - 43
(Method:Urease - GLDH) (Sample:Serum) New born :8.4-25.8
Infant:10.8-38.4
BUN (Blood Urea Nitrogen) 8.9 mg/ dL 5.0 - 24.0
(Method:Calculation) (Sample:Serum)
Creatinine 0.74 mg/ dl Male-0.67- 1.17
(Method:MODIFIED JAFFE) (Sample:Serum) Female‑0.51– 0.95
Neonate- 0.31- 0.98
Infants-0.16-0.39
Child‑ 0.26 – 0.77
Uric Acid 7.3 mg/ dL Male: 3.5-7.2
(Method:Uricase - PAP) (Sample:Serum) Female: 2.6-6.0
BUN/ Creatinine Ratio 12.03 -
(Method:Calculated) (Sample:Serum)
Urea/ Creatinine Ratio 25.68 -
eGFR 102.00 ml/ min/ 1.73m2 ≥ 90 : Normal
(Method:Calculated) (Sample:Serum) 60 - 89 : Mild Decrease
45 - 59 : Mild to Moderate
Decrease
30 - 44 : Moderate to Severe
Decrease
15 - 29 : Severe Decrease

Page 6 of 10
Patient NAME : Mr.Krishnendu Basak Barcode NO : 12362429
Age/Gender : 24 Y/ Male Registration ON : 12- Jan- 2024 02: 47: 14 PM
LabNo : 012401120688 Sample Collected ON : 12/ Jan/ 2024 02: 47: 14 PM
Referred BY : Dr. SELF Sample Received ON : 12/ Jan/ 2024 03: 01: 29 PM
CLIENT CODE : WBCL/ CORP/ PTPL Report Generated ON : 12/ Jan/ 2024 04: 32: 53 PM
Refer Lab/Hosp : Sample STATUS : Final Approved
Lab Address : AS 130, Block-H, Rajarhat Main Road, Kolkata 700157

DEPARTMENT OF CLINICAL BIOCHEMISTRY

Medibuddy 1 9 7 .0 -MediBuddy - TCS Wellness Package Onsite

Test Name Value Unit Bio Ref.Interval

Thyroid Stimulating Hormone (TSH) 2.54 uIU/ mL 0.3-4.5

(Method:CLIA ) (Sample:Serum) First Trimester : 0.1-2.5
Second Trimester : 0.2-3.0
Third trimester : 0.3-3.0
Children <1 years: <10.0
Please clinically correlate. Partial reproduction of test reports is strictly prohibited.
The reports are strictly for the use of medical practitioners and are not medical diagnosis.
Com m ent s:
Increased in:
Primary untreated hypothyroidism. Patient with hypothyroidism receiving insufficient thyroid hormone replacement therapy. Patients with Hashimoto thyroiditis, including
those will clinical hypothyroidism. Use of various drugs: Amphetamines (abuse), Iodine containing agents (e.g., Iopanoic acid, Ipodate, Amiodarone), Dopamine
antagonists (e.g., metoclopramide, domperidone, Chlorpromazine, Haloperidol).
Decrease in:
Toxic multinodular goiter. Autonomously functioning thyroid adenoma. Ophthalmopathy of euthyroid Graver disease, Thyroiditis, Extrathyroidal thyroid hormone source,
factitious, overreplacement of thyroid hormone in the treatment of hypothyroidism.

Page 7 of 10
Patient NAME : Mr.Krishnendu Basak Barcode NO : 12362429
Age/Gender : 24 Y/ Male Registration ON : 12- Jan- 2024 02: 47: 14 PM
LabNo : 012401120688 Sample Collected ON : 12/ Jan/ 2024 02: 47: 14 PM
Referred BY : Dr. SELF Sample Received ON : 12/ Jan/ 2024 03: 22: 43 PM
CLIENT CODE : WBCL/ CORP/ PTPL Report Generated ON : 12/ Jan/ 2024 04: 04: 15 PM
Refer Lab/Hosp : Sample STATUS : Final Approved
Lab Address : AS 130, Block-H, Rajarhat Main Road, Kolkata 700157

DEPARTMENT OF CLINICAL PATHOLOGY

Medibuddy 1 9 7 .0 -MediBuddy - TCS Wellness Package Onsite

Test Name Value Unit Bio Ref.Interval

RE - Urine - Extended
PHYSICALEXAMINATION
Colour Pale Yellow
(Method:Visual Examination) (Sample:Random Urine)
Appearance Clear
(Method:Visual Examination) (Sample:Random Urine)
Specific gravity 1.020
(Method:Refractometry and Gravimetry) (Sample:Random Urine)
CHEMICALEXAMINATION
pH 6.2
(Method:Double indicator) (Sample:Random Urine)
Protein Absent
(Method:Protein error of indicators) (Sample:Random Urine)
Sugar Absent
(Method:GOD-POD) (Sample:Random Urine)
Blood Absent
(Method:Tetramethylbenzidine) (Sample:Random Urine)
Leucocytes Absent
Ketones Negative Negative
Nitrites Negative Negative
(Method:Reagent Strip Reflectance) (Sample:Random Urine)
Bilirubin Negative Negative
MICROSCOPICEXAMINATION
Pus cells 03-04 / hpf
(Method:Microscopic) (Sample:Random Urine)
Epithelial cells 01-02 / hpf
(Method:Microscopic) (Sample:Random Urine)
RBC Absent / hpf
(Method:Microscopic) (Sample:Random Urine)
Cast Absent
(Method:Microscopic) (Sample:Random Urine)
Crystal Absent
(Method:Microscopic) (Sample:Random Urine)
Micro Organism Absent
(Method:Microscopic) (Sample:Random Urine)
Yeast cell Absent

Page 8 of 10
Patient NAME : Mr.Krishnendu Basak Barcode NO : 12362429
Age/Gender : 24 Y/ Male Registration ON : 12- Jan- 2024 02: 47: 14 PM
LabNo : 012401120688 Sample Collected ON : 12/ Jan/ 2024 02: 47: 14 PM
Referred BY : Dr. SELF Sample Received ON : 12/ Jan/ 2024 03: 22: 43 PM
CLIENT CODE : WBCL/ CORP/ PTPL Report Generated ON : 12/ Jan/ 2024 04: 04: 15 PM
Refer Lab/Hosp : Sample STATUS : Final Approved
Lab Address : AS 130, Block-H, Rajarhat Main Road, Kolkata 700157

DEPARTMENT OF CLINICAL PATHOLOGY

Medibuddy 1 9 7 .0 -MediBuddy - TCS Wellness Package Onsite

Test Name Value Unit Bio Ref.Interval

(Method:Microscopic) (Sample:Random Urine)
Others Nil -
(Method:Microscopic) (Sample:Random Urine)

Page 9 of 10
Patient NAME : Mr.Krishnendu Basak Barcode NO : 12362429
Age/Gender : 24 Y/ Male Registration ON : 12- Jan- 2024 02: 47: 14 PM
LabNo : 012401120688 Sample Collected ON : 12/ Jan/ 2024 02: 47: 14 PM
Referred BY : Dr. SELF Sample Received ON : 12/ Jan/ 2024 03: 01: 29 PM
CLIENT CODE : WBCL/ CORP/ PTPL Report Generated ON : 12/ Jan/ 2024 04: 20: 43 PM
Refer Lab/Hosp : Sample STATUS : Final Approved
Lab Address : AS 130, Block-H, Rajarhat Main Road, Kolkata 700157

DEPARTMENT OF CHROMATOGRAPHY
Medibuddy 1 9 7 .0 -MediBuddy - TCS Wellness Package Onsite

Test Name Value Unit Bio Ref.Interval

Glycosylated Hemoglobin (HbA1c) 6.3 % Non-diabetic : 4 – 5.7

(Method:HPLC) (Sample:EDTA Whole Blood) Pre-diabetic : 5.7 - 6.4
Diabetic : >= 6.5
Estimated Average Glucose (eAG) 134 mg/ dL Excellent Control : 90-120
(Method:Calculated) (Sample:EDTA Whole Blood) Good Control : 121-150
Average Control : 151-180
Action Suggested : 181-210
Panic Value : > 210
Please clinically correlate. Partial reproduction of test reports is strictly prohibited.
The reports are strictly for the use of medical practitioners and are not medical diagnosis.
Com m ent s:

1. HbA1c is used for monitoring diabetic control. It reflects the estimated average glucose (eAG).
2. HbA1c has been endorsed by clinical groups & ADA (American Diabetes Association) guidelines 2017, for diagnosis of diabetes using a cut-off point of 6.5%.
3. Trends in HbA1c are a better indicator of diabetic control than a solitary test.
4. Low glycosylated haemoglobin (below 4%) in a non-diabetic individual are often associated with systemic inflammatory diseases, chronic anaemia (especially severe iron deficiency &
haemolytic anaemia), chronic renal failure and liver diseases. Clinical correlation suggested.
5. To estimate the eAG from the HbA1C value, the following equation is used: eAG (mg/ dl) = 28.7 x HbA1c - 46.7
6. Interference of haemoglobinopathies in HbA1c estimation:
a. For HbF > 25%, an alternate platform (Fructosamine) is recommended for testing of HbA1c.
b. Homozygous haemoglobinopathy is detected, fructosamine is recommended for monitoring diabetic status.
c. Heterozygous state detected (D10/ turbo is corrected for HbS and HbC trait).
7. In known diabetic patients, following values can be considered as a tool for monitoring the glycemic control. Excellent Control – 6 to 7 %, Fair to Good Control ‑ 7 to 8 %, Unsatisfactory Control ‑
8 to 10 % and Poor Control - More than 10 %.

Note : Hemoglobin electrophoresis (HPLC method) is recommended for detecting haemoglobinopathy.

Sample: Inhouse Sample

*** End Of Report ***

1.Partial reproduction of this report is not permitted. 2. If the result(s) of the test(s) is alarming or unexpected, the patient is advised to contact the laboratory immediately for possible advice. 3.Result(s) pertain
to the specimen submitted. 4. Laboratory investigations should be used along with relevant clinical examinations to achieve the final diagnosis. These are never conclusive and dependent on the quality of the
samples as well as the assay procedures used. 5. Test(s) requested might not be performed for the following reasons: (a) Quantity of the specimen received is unacceptable (b)Quality of the specimen received is of
unacceptable quality (hemolyzed/Clotted/Lipemic). In any of these cases, a fresh specimen must be sent for reporting of the same parameters within the schedule (next 2 days). 6. Test(s) are performed as per the test
schedule of the laboratory. In unforeseen circumstances (non availability of reagents, instrument breakdown, and natural calamities) test(s) may not be reported as per test schedule.Nirnayan will ensure that the
delay is minimized.

Page 10 of 10
Bio-Rad CDM System PATIENT REPORT
BIO-RAD VARIANT II TURBO. SN--16571 V2TURBO_A1c_2.0

Patient Data Analysis Data

Sample ID: 12362429 Analysis Performed: 12/01/2024 16:05:23
Patient ID: Injection Number: 2412
Name: Run Number: 59
Physician: Rack ID: 0001
Sex: Tube Number: 1
DOB: Report Generated: 12/01/2024 16:09:31
Operator ID:
Comments:

NGSP Retention Peak

Peak Name % Area % Time (min) Area
A1a --- 1.2 0.163 14317
A1b --- 1.0 0.234 12351
F --- 1.1 0.279 13428
LA1c --- 1.7 0.416 20539
A1c 6.3* --- 0.526 62611
P3 --- 3.8 0.792 45375
P4 --- 1.4 0.872 17024
Ao --- 84.4 1.004 1007186

*Values outside of expected ranges Total Area: 1,192,831

HbA1c (NGSP) = 6.3* %

20.0

17.5

15.0

12.5
%A1c

0.53

10.0
A1c -

0.79

7.5
0.87
0.23

0.42

-
0.28

5.0
0.16

-
-

-
-

2.5
1.00
-

0.0
-

0.00 0.25 0.50 0.75 1.00 1.25 1.50

Time (min.)
 Date: IST: 2024-01-12 11:13:53 Report ID: MDA_2128566150_V6RU0V74
Personal Details | Pre-Existing Medical- | Symptoms | Vitals | Measurements
Measurements | Interpretation(Unconfirmed)
Interpretation(Unconfirmed)
Interpretation
UHID: 2128566150 | Conditions | | | HR:
HR :6363BPM
BPM | Sinus
Sinus Arrhythmia
Arrhythmia
PatientID: 2128566150 | | | | PR: 152
PR: 152 ms
ms | Normal
Sinus
NormalRhythm
Axis Regular
Axis
Name: Krishnendu Basak | | | | PD: 112
PD: 112 ms
ms | ST Elevation
Normal
ST Elevation
Axis in
in Anterior
Anterior Leads
Leads
Age: 24 | | | | QRS: 9090ms
QRSD: ms |
QRS Axis: 51 deg
Gender: Male | | | | QRS Axis: 51 deg ms
QT/QTc: 338/346 |
Mobile: 0000000000 | | | | QT/QTc: 338/338 ms |
| | | | |
| | | | |
| | | | |
This trace is generated by KardioScreen; Cloud-Connected, Portable, Digital, 6-12 Lead Scalable ECG Platform from IMEDRIX

I aVR V1 V4

II aVL V2 V5

III aVF V3 V6

II

Speed: 25 mm/sec F: 0.05 - 40 Hz Limb: 10 mm/mV Chest: 10 mm/mV

Disclaimer: ECG plot for inference by qualified Medical Practitioners only Version1.8.2 Copyright iMedrix, All Rights Reserved
 Vitals Health Assessment

Name: Krishnendu Basak

Height (in cm) 171

Weight (in kgs) 109

Systolic BP (mm Hg) 140

Diastolic BP (mm Hg) 85

BMI 37.28